Search results for "nutrition"

showing 10 items of 6788 documents

A life-threatening complication of parenteral nutrition: how to prevent cardiac tamponade?

2014

Complications caused by incorrect central venous insertion are numerous. Cardiac tamponade is a rare, but well-documented complication that is often lethal. We present the case of a patient with cardiac tamponade caused by incorrect tip position and infusion of hyperosmolar fluids such as for parenteral nutrition.

medicine.medical_specialtyCatheterization Central VenousParenteral Nutritionbusiness.industrymedicine.medical_treatmentmedicine.diseaseSurgeryCardiac TamponadeParenteral nutritionCardiac tamponadeAnesthesiamedicineHumansFemaleEmergenciesCardiology and Cardiovascular MedicineComplicationbusinessTip positionCentral venous catheterAgedAnnales de cardiologie et d'angeiologie
researchProduct

Differences in zinc status and the leptin axis in anorexic and recovered adolescents and young adults : a pilot study

2012

Food & nutrition research 56, 8 S. (2012). doi:10.3402/fnr.v56i0.10941

medicine.medical_specialtyChild and Adolescent Psychiatry; Medicine;lcsh:TX341-641leptin receptor (sOB-R)leptinanorexia nervosaInternal medicineMedicineddc:610Young adultResearch dataNutrition and DieteticsLeptin receptorbusiness.industryAnorexia nervosa; leptin; leptin receptor (sOB-R); free leptin index (FLI); zincLeptinzincfungidigestive oral and skin physiologyPublic Health Environmental and Occupational HealthControl subjectsfree leptin index (FLI)EndocrinologyAnorexia nervosa (differential diagnoses)Eating disordersOriginal ArticleAnimal studiesNutrition researchbusinesslcsh:Nutrition. Foods and food supplyhormones hormone substitutes and hormone antagonistsFood Science
researchProduct

Hyperlipidemia Prevalence and Cholesterol Control in OSA: Data from European Sleep Apnea Database (ESADA)

2019

European-Respiratory-Society (ERS) International Congress -- SEP 28-OCT 02, 2019 -- Madrid, SPAIN

medicine.medical_specialtyCholesterolbusiness.industryConfoundingnutritional and metabolic diseasesSleep apneaDiseasemedicine.diseasenervous system diseasesrespiratory tract diseasesObstructive sleep apneachemistry.chemical_compoundstomatognathic systemchemistryInternal medicineCohortHyperlipidemiamedicineIn patientbusinessHypoxia
researchProduct

Nonalcoholic fatty liver disease, association with cardiovascular disease and treatment. (I). Nonalcoholic fatty liver disease and its association wi…

2016

Non-alcoholic fatty liver disease (NAFLD) comprises a series of histologically lesions similar to those induced by alcohol consumption in people with very little or no liver damage. The importance of NAFLD is its high prevalence in the Western world and, from the point of view of the liver, in its gradual progression from steatosis to steatohepatitis, cirrhosis, and liver cancer. During the last decade it has been observed that NAFLD leads to an increased cardiovascular risk with acceleration of arteriosclerosis and events related to it, being the main cause of its morbidity and mortality. This review, updated to January 2016, consists of two parts, with the first part analysing the associa…

medicine.medical_specialtyCirrhosisDisease030204 cardiovascular system & hematologyGastroenterology03 medical and health sciences0302 clinical medicineNon-alcoholic Fatty Liver DiseaseRisk FactorsInternal medicineNonalcoholic fatty liver diseaseMedicineHumansGeneral Environmental Sciencebusiness.industryFatty liverGeneral Engineeringnutritional and metabolic diseasesArteriosclerosismedicine.diseaseAtherosclerosisdigestive system diseasesCardiovascular DiseasesDisease ProgressionGeneral Earth and Planetary Sciences030211 gastroenterology & hepatologySteatohepatitisSteatosisbusinessLiver cancerClinica e investigacion en arteriosclerosis : publicacion oficial de la Sociedad Espanola de Arteriosclerosis
researchProduct

Non-alcoholic steatohepatitis: Pathogenesis and novel therapeutic approaches

2013

Non-alcoholic fatty liver disease (NAFLD) refers to a disease spectrum, ranging from mere hepatic steatosis to hepatic necroinflammation (NASH, non-alcoholic steatohepatitis). NASH often leads to fibrosis, which can progress to cirrhosis with a high risk of liver failure and hepatocellular carcinoma. The course of NAFLD is highly variable, and only a minority of patients (2-3%) progress to end-stage liver disease. However, due to a dramatic increase of the risk factors for NAFLD, that is obesity and insulin resistance/type 2 diabetes, that affect 15-30% and 7-15% of subjects, in most industrialized countries, respectively, NAFLD has become the most frequent liver disease and is even conside…

medicine.medical_specialtyCirrhosisHepatologybusiness.industryFatty liverGastroenterologynutritional and metabolic diseasesmedicine.diseaseBioinformaticsdigestive systemdigestive system diseasesLiver diseaseEndocrinologyInsulin resistanceLipotoxicityInternal medicinemedicineSteatosisSteatohepatitisMetabolic syndromebusinessJournal of Gastroenterology and Hepatology
researchProduct

Frailty and Sarcopenia in Acute‐on‐Chronic Liver Failure

2021

In patients with cirrhosis, sarcopenia is a critical reduction in skeletal muscle mass and frailty represents a status of global physical dysfunction caused by under nutrition, muscle wasting, and functional impairment. Both are prevalent conditions in liver transplant candidates and have shown to be independent predictors of adverse outcome. Evidence supports their incorporation into clinical practice both as a prognostic factor guiding clinical decision making and as a tool to identify candidates for physical and nutritional interventions. The wide heterogeneity of instruments used for sarcopenia and frailty measurement, the absence of a single suitable instrument for sarcopenia and frail…

medicine.medical_specialtyCirrhosisHepatologybusiness.industryRC799-869ReviewDiseases of the digestive system. Gastroenterologymedicine.diseaseFrailty assessmentUnder nutritionTransplantationSarcopeniamedicineAcute on chronic liver failureIn patientmedicine.symptomIntensive care medicinebusinessWastingHepatology Communications
researchProduct

Nonalcoholic fatty liver disease and the risk of metabolic comorbidities: how to manage in clinical practice.

2020

Nonalcoholic fatty liver disease (NAFLD) is a clinical condition that encompasses various forms of liver damage not caused by chronic alcohol consumption. In the absence of other etiologies, it ranges from ste- atosis to nonalcoholic steatohepatitis and cirrhosis. The prevalence of NAFLD has considerably increased over the last years owing to the current lifestyle (unhealthy diet and sedentarism). Besides, it is associated with metabolic risk factors such as obesity, arterial hypertension, dyslipidemia, and type 2 diabetes. Given the poor prognosis of patients with advanced NAFLD, a practical therapeutic approach is necessary to halt its natural history. However, no licensed drugs have been…

medicine.medical_specialtyCirrhosisbusiness.industrynutritional and metabolic diseasesDiseaseType 2 diabetesComorbiditymedicine.diseaseObesitydigestive system diseasesArterial hypertension Dyslipidemia Nonalcoholic fatty liver disease Type 2 diabetes Comorbidity Humans Obesity Weight Loss Diabetes Mellitus Type 2 Non-alcoholic Fatty Liver DiseaseDiabetes Mellitus Type 2Weight lossNon-alcoholic Fatty Liver DiseaseInternal medicineNonalcoholic fatty liver diseaseWeight LossInternal MedicinemedicineHumansObesitymedicine.symptomSteatosisbusinessDyslipidemiaPolish archives of internal medicine
researchProduct

Reduced incidence of type 2 diabetes in patients with chronic hepatitis C virus infection cleared by direct-acting antiviral therapy: A prospective s…

2020

Aim HCV infection increases the risk of type 2 diabetes mellitus (T2DM). However, it remains still unclear whether HCV clearance by direct-acting antivirals (DAA) reduces T2DM. Therefore, the effect of HCV eradication on T2DM incidence was assessed. Methods A prospective multicenter case-control study was performed, which included 2,426 HCV patients, 42% of which with liver fibrosis F0-F2 and 58% F3-F4. Study population consisted of a control group including 1099 untreated patients and 1327 cases treated with DAA. T2DM incidence was assessed during a follow-up median period of 30 [IQR: 28-42] months. Risk factors of T2DM were assessed by Cox regression model (Relative risk (RR), Hazard risk…

medicine.medical_specialtyCirrhosisendocrine system diseasesEndocrinology Diabetes and Metabolism030209 endocrinology & metabolismType 2 diabetes030204 cardiovascular system & hematologyAntiviral AgentsGastroenterology03 medical and health sciences0302 clinical medicineEndocrinologychronic hepatitiInternal medicineInternal MedicinemedicineHumansGlucose homeostasisProspective StudiesProspective cohort studydirect-acting antiviralbusiness.industryIncidenceIncidence (epidemiology)nutritional and metabolic diseasesType 2 Diabetes MellitusHepatitis C Chronicmedicine.diseaseDiabetes Mellitus Type 2Case-Control StudiesRelative riskHCVPopulation studytype 2 diabetesbusinesscirrhositype 2 diabetes.
researchProduct

A New Score Unveils a High Prevalence of Mild Cognitive Impairment in Patients with Nonalcoholic Fatty Liver Disease

2021

Patients with nonalcoholic fatty liver disease (NAFLD) may show mild cognitive impairment (MCI). The neurological functions affected remain unclear. The aims were to: (1) Characterize the neuropsychological alterations in NAFLD patients; (2) assess the prevalence of impairment of neurological functions evaluated; (3) develop a new score for sensitive and rapid MCI detection in NAFLD; (4) assess differences in MCI features between patients with nonalcoholic fatty liver (NAFL) and nonalcoholic steatohepatitis (NASH); and (5) compare neuropsychological alterations in NAFLD patients with cirrhotic patients with MCI. Fifty-nine NAFLD patients and 53 controls performed psychometric tests assessin…

medicine.medical_specialtyCirrhosisneurological impairmentpsychometric scoreGastroenterologybehavioral disciplines and activitiesdigestive systemArticle03 medical and health sciences0302 clinical medicineInternal medicineNAFLDNonalcoholic fatty liver diseasemedicineMemory spanHepatic encephalopathyPsychomotor learningbusiness.industryFatty liverRNeuropsychologyNASHnutritional and metabolic diseasesGeneral Medicinemedicine.diseasepsychometric score; NAFLD; NAFL; NASH; neurological impairmentdigestive system diseasesNAFLMedicine030211 gastroenterology & hepatologybusiness030217 neurology & neurosurgeryStroop effectJournal of Clinical Medicine
researchProduct

Update on cardiovascular prevention in clinical practice: A position paper of the European Association of Preventive Cardiology of the European Socie…

2020

This is a pre-copyedited, author-produced version of an article accepted for publication in European Journal of Preventive Cardiology following peer review. The version of record Piepoli, M.F., Abreu, A., Albus, C., Ambrosetti, M., Brotons, C., Catapano, A.L. ... Tiberi, M. (2020). Update on cardiovascular prevention in clinical practice: A position paper of the European Association of Preventive Cardiology of the European Society of Cardiology*. European Journal of Preventive Cardiology (EJPC), 27(2), 181-205 is available online at: https://doi.org/10.1177/2047487319893035. European guidelines on cardiovascular prevention in clinical practice were first published in 1994 and have been regu…

medicine.medical_specialtyConsensusEpidemiologyCost effectivenessCost-Benefit AnalysisPopulationCardiologyPsychological interventionphysical activitypopulationGuidelinesrisk managementsmokingrehabilitationlipidsprimary carepreventionhealthy lifestyleInternal medicinePreventive Health ServicesEpidemiologyHumansMedicineguidelineseducationpsychosocial factorsstakeholderRisk managementeducation.field_of_studyVDP::Medisinske Fag: 700::Helsefag: 800::Samfunnsmedisin sosialmedisin: 801diabetesbusiness.industryStakeholderblood pressurerisk assessmentHealth Care CostsProtective FactorsPrognosisnutritionCardiovascular DiseasesHeart Disease Risk FactorsCardiologyPosition paperCardiology and Cardiovascular MedicinebusinessRisk assessmentclinical settings
researchProduct